【ChiCTR2600123728】The Development of a New Imaging Modality for Micro-TESE based on the Preliminary First Clinical Trial
ChiCTR2600123728
结束
/
/
/
2026-04-29
/
/
Male Infertility
The Development of a New Imaging Modality for Micro-TESE based on the Preliminary First Clinical Trial
The Need to Develop Micro-TESE in Male Infertility in Light of Current Literature: Investigation of the Clinical Effectiveness of a New Imaging Method
34899
/
The primary objective was to evaluate the diagnostic performance of a novel telecentric lens–based imaging system for identifying seminiferous tubules associated with sperm retrieval during micro-TESE in patients with NOA.
诊断试验诊断准确性
诊断试验新技术
None
/
This work was funded by a grant from the TUBITAK (The Scientific and Technological Research Council of Turkiye) (Protocol No.121S182). This fund was utilsed yo obtaind instruments (lens, camere etc.).
/
/
/
2020-01-05
2023-03-14
/
1. Male patients aged 18–40 years. 2. Diagnosis of non-obstructive azoospermia confirmed by at least two semen analyses. 3. Scheduled to undergo micro-TESE for infertility treatment. 4. Female partner eligible for intracytoplasmic sperm injection (ICSI). 5. Ability to understand the study procedures and willingness to provide written informed consent. 1. Male patients aged 18–40 years.2. Diagnosis of non-obstructive azoospermia confirmed by at least two semen analyses.3. Scheduled to undergo micro-TESE for infertility treatment.4. Female partner eligible for intracytoplasmic sperm injection (ICSI).5. Ability to understand the study procedures and willingness to provide written informed consent.；
请登录查看1. Obstructive azoospermia. 2. Known chromosomal abnormalities incompatible with sperm retrieval. 3. Prior testicular surgery significantly altering anatomy. 4. Inability or refusal to provide consent.；
请登录查看Department of Urology School of Medicine, Marmara University
34899
/
Department of Urology School of Medicine, Marmara University的其他临床试验
Department of Urology School of Medicine, Marmara University的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 60
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04